Business Wire

Vector Laboratories Launches Glysite™ Explorer in situ PLA Glycan Detection Kit to Advance Functional Proteomics Research

15.7.2025 14:29:00 CEST | Business Wire | Press Release

Share

Vector Laboratories, a leader in innovative proteomic and glycomic research solutions, and Navinci, an established developer of in situ proximity ligation assay-based solutions, today announced the launch of the Glysite™ Explorer in situ PLA Glycan Detection Kit. The kit represents the first commercially available product to study protein glycosylation and provides a simple approach to understand glycan-protein proximity with a spatial context.

The Glysite™ Explorer in situ PLA Glycan Detection Kit is a fully integrated tool for the spatial detection of glycans proximal to a protein of interest in FFPE tissues, FFPE cell pellets and fixed cells. Integrating a curated panel of Vector’s Glysite™ Explorer lectins with Navinci’s proprietary in situ Proximity Ligation Assay (isPLA), this system enables researchers to investigate a new dimension of biology.

“We’re excited to share this new tool with researchers,” said Lisa V. Sellers, PhD, CEO of Vector Laboratories. “Studying protein glycosylation is challenging and Vector is providing a transformational approach to expand the depth of information that can be gained from tissue samples. As a global leader in glycan detection tools, we have co-developed a novel and easy-to-use kit to make the study of glycosylation more accessible to researchers. We believe this new kit will greatly improve the accessibility of investigating protein glycosylation and will allow researchers to better interrogate this dimension in various sample types.”

“We’re excited about this partnership and how it leverages proven technologies to support researchers from discovery to validation,” said Jenny Sundqvist, CEO of Navinci. “This is the first commercial product of its kind available to researchers studying protein glycosylation. By using Navinci’s proven isPLA technology and Vector Labs’ validated lectins (glycan binders), users of this kit can gain invaluable insight into protein function and disease processes.”

A main feature of the kit is that it adds a new multiomic dimension to data by assessing the protein glycosylation state in a streamlined, easy-to-use, and reproducible approach. Through integrated analysis, scientists can advance their understanding of protein glycosylation in disease biology, biomarker discovery, and translational studies. In addition, the kit uses existing equipment and workflows so that researchers can generate new data using standard systems and protocols.

About Vector Labs

Vector Laboratories is a reagents manufacturer and services provider, partnering with scientists to address today’s toughest biomedical challenges. Our product portfolio ranges from protein and glycan detection and visualization reagents to bioconjugation linker and dye technologies, all of which enable basic scientific discovery. Through custom products and services, including recombinant antibody engineering services, we help fuel our customers’ development of next-generation therapeutics. Vector Laboratories is building on 45+ years of expertise and an unparalleled reputation for a culture of service, proven products, and incomparable technical partnership. To learn more, visit the Vector Laboratories website.

About Navinci

Navinci is a Swedish biotechnology company specializing in developing innovative solutions for studying proteins, protein-protein interactions and post translationally modified proteins in cells and tissues. With a focus and strong legacy in developing in situ proximity ligation assay technology, Navinci has established itself as a center of excellence in the spatial biology field and has a broad portfolio of products that help academic researchers and biopharma study the protein interplay in depth. For more information, visit the Navinci website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250715118209/en/

Contacts

Media Contact
Kellyann Zuzulo
kzuzulo@cglife.com
215-287-7291

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye